Resistance to the Non-Covalent BTK Inhibitor Pirtobrutinib

布鲁顿酪氨酸激酶 伊布替尼 共价键 抗性(生态学) 化学 生物 遗传学 慢性淋巴细胞白血病 生物化学 白血病 酪氨酸激酶 信号转导 生态学 有机化学
作者
Aishath Naeem,Filippo Utro,Qing Wang,Justin Cha,Mauno Vihinen,Stephen P. Martindale,Yinglu Zhou,Svitlana Tyekucheva,Annette S. Kim,Stacey M. Fernandes,Rayan Fardoun,Gordon Saksena,Kahn Rhrissorrakrai,Chaya Levovitz,Brian P. Danysh,Kara Slowik,Raquel A. Jacobs,Matthew S. Davids,Rula Zain,Edvard CI Smith,Ignaty Leshchiner,Laxmi Parida,Gad Getz,Jennifer R. Brown
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 6981-6982 被引量:3
标识
DOI:10.1182/blood-2022-160279
摘要

Pirtobrutinib is a non-covalent BTK inhibitor (BTKi) designed to maintain activity despite the most common resistance mutation to covalent inhibitors, at BTK C481. To investigate mechanisms of disease progression on pirtobrutinib, we evaluated the effect of pirtobrutinib in vitro on the BCR pathway in pre- and post-treatment patient samples (n=5), and on 2 of these patients, we performed whole exome sequencing longitudinally including prior to and at relapse on pirtobrutinib. Phylogenetics and subclonal dynamics associated with resistance were evaluated using the PhylogicNDT and Concerti tools. To investigate the impact of identified BTK mutations on BCR activation, we generated 6 single and 3 double mutants using site directed mutagenesis and expressed them in the BTK null DT40 B cell line. We demonstrate that primary CLL cells from responding patients on the pirtobrutinib trial show reduced BCR signaling, reduced CCL3/CCL4 chemokine secretion, as well as effective induction of apoptosis and inhibition of proliferation, in response to pirtobrutinib. At time of progression, these primary CLL cells show increasing resistance to pirtobrutinib in signaling inhibition and cytokine production, with reduced inhibition of proliferation and induction of apoptosis. In WES analysis, patient #1 had 16 samples evaluated prior to, during, and at relapse on acalabrutinib, vecabrutinib and pirtobrutinib. Clonal analysis of samples collected during acalabrutinib shows steady selection of a clone harboring BTK p.C481S mutation with CCF 92% at relapse but then steadily decreases during pirtobrutinib treatment. Concerti's time-scaled phylogenetic tree shows the birth of a new clone containing the BTK gatekeeper mutation, p.T474I, during acalabrutinib treatment, which then grows rapidly under pirtobrutinib treatment, taking over nearly the entire cancer cell population and replacing the prior p.C481S clone. This complete clonal shift during pirtobrutinib treatment suggests that pirtobrutinib effectively inhibits the p.C481S clone, while the p.T474I gatekeeper clone is likely driving resistance in this patient. We also observed an additional gatekeeper clone BTK p.T474L develop at low levels, as well as another previously undescribed BTK mutation at p.M477I. Manual inspection showed that BTK mutations p.M477I and p.T474I are in cis and therefore in the same clone. Patient #2 had 10 samples evaluated prior to, during and at relapse on ibrutinib and pirtobrutinib. During ibrutinib therapy, we observed a steady increase in a clone with TP53 p.S240G and SF3B1 p.K666N mutations, reaching CCFs >40% at relapse on ibrutinib. We also noted a significant increase in BTK p.C481R (CCF 33%), BTK p.C481S (CCF 11%) and TP53 p.R196* (CCF 5%) at progression on ibrutinib. Under pirtobrutinib treatment the clone carrying BTK p.C481R decreased to CCF 20%, while BTK p.C481S (28%) and TP53 p.R197* (35%) both increased. Concerti's phylogenetic tree captures the birth of a resistant clone, harboring BTK p.L528W which significantly increases to CCF 30% at progression on pirtobrutinib. Functional characterization of the identified BTK mutations demonstrated that only T474I, T474L and C481S mutants showed adequate kinase activity, while all the other mutants including M477I, C48IR and L528W essentially lacked kinase activity as judged by phosphorylation at BTK Y223 and at PLCG2 Y753. As expected, the C481S variant was resistant to ibrutinib, but not to pirtobrutinib, while the T474I/L variants were sensitive to ibrutinib but resistant to pirtobrutinib. Interestingly, phosphorylation of AKT and ERK were retained downstream, even with mutations that failed to activate proximal BCR signaling. Furthermore, phosphorylation of AKT and ERK was also observed in the B7.10 cell line which lacks endogenous BTK, demonstrating significant activation of these pathways independent of BTK. In this study, we demonstrate that ex vivo efficacy of pirtobrutinib declines as patients’ CLL starts to progress, in concert with the development of gatekeeper and alternative site BTK mutations that lead to resistance to pirtobrutinib. Interestingly, many of the second-site BTK mutations fail to activate BTK phosphorylation but are still associated with downstream activation of phospho-AKT and phospho-ERK; the mechanism of this activation remains to be elucidated.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
Theprisoners应助吗喽采纳,获得20
2秒前
王冠军完成签到,获得积分10
2秒前
3秒前
3秒前
认真跳跳糖完成签到,获得积分10
4秒前
Zhao Jiaxu完成签到,获得积分10
4秒前
英俊的铭应助mengxia采纳,获得10
5秒前
在水一方应助abletoo采纳,获得20
6秒前
6秒前
6秒前
明理十三发布了新的文献求助10
7秒前
relink完成签到,获得积分10
8秒前
充电宝应助迷你的颖采纳,获得10
9秒前
10秒前
10秒前
niania发布了新的文献求助10
11秒前
Anxinxin完成签到,获得积分10
12秒前
ding应助ZengJuan采纳,获得10
13秒前
13秒前
14秒前
邓思琪完成签到,获得积分10
14秒前
欣慰碧琴完成签到,获得积分10
14秒前
Maisie发布了新的文献求助10
14秒前
ding应助YZzzJ采纳,获得10
15秒前
追寻访卉发布了新的文献求助10
15秒前
16秒前
16秒前
16秒前
16秒前
17秒前
18秒前
楼萌黑发布了新的文献求助10
18秒前
19秒前
Y890发布了新的文献求助10
19秒前
123完成签到,获得积分10
20秒前
Rondab应助凉笙墨染采纳,获得10
20秒前
21秒前
隋晓钰发布了新的文献求助10
21秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Indomethacinのヒトにおける経皮吸収 400
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 370
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
Current Perspectives on Generative SLA - Processing, Influence, and Interfaces 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3992562
求助须知:如何正确求助?哪些是违规求助? 3533545
关于积分的说明 11262757
捐赠科研通 3273163
什么是DOI,文献DOI怎么找? 1805959
邀请新用户注册赠送积分活动 882889
科研通“疑难数据库(出版商)”最低求助积分说明 809513